CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Glenmark Pharmaceuticals Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Glenmark Pharmaceuticals Ltd
B D S Marg
Chakala, Off Western Express Highway
Phone: +91 2240189999p:+91 2240189999 MUMBAI, 400099  India Ticker: GLENMARKGLENMARK

Business Summary
Glenmark Pharmaceuticals Limited is a global pharmaceutical company. The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW). It has approximately seven molecules, over two NCEs and approximately five NBEs in various stages of pre-clinical and clinical development. It is focused on developing and marketing branded and generic formulations. It focuses on manufacturing products across therapeutic areas of dermatology, respiratory and oncology. Its active pharmaceuticals ingredients (API) business spans over 80 countries, including regulated markets of the United States, Europe, Japan and Canada. Its products are primarily marketed in the United States and Western Europe. It has offices in over 40 countries, and operates approximately 20 manufacturing facilities in over five countries. It operates over five research and development (R&D) centers.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
Morningstar
Rating
YesYes-Yes--Yes--

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/20193/31/2019Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Executive Chairman of the Board, Chief Executive Officer, Managing Director Glenn M.Saldanha 49 5/10/2011 1/1/2003
Global Chief Financial Officer, Executive Director V. S.Mani 5/29/2018 11/16/2017
Compliance Officer, Company Secretary HarishKuber 2/2/2017 2/2/2017
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Glenmark Generics Ltd B-2, Mahalaxmi Chambers MUMBAI India

Business Names
Business Name
532296
GLENMARK
Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Ltd.
GMKPF

General Information
Number of Employees: 12,921 (As of 3/31/2019)
Outstanding Shares: 282,170,000 (As of 9/30/2019)
Shareholders: 120,430
Stock Exchange: NSE
Fax Number: +91 2240189986


Copyright © 2019 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, December 05, 2019